Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA

Yoon Dae Han, Tae Jeong Oh, Tae Ha Chung, Hui Won Jang, Youn Nam Kim, Sungwhan An, Nam Kyu Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. We have previously demonstrated that the presence of SDC2 methylation in stool DNA is significantly associated with the occurrence of CRC regardless of clinical stage. The aim of this study was to evaluate the clinical performance of stool DNA-based SDC2 methylation test for CRC. Methods: Aberrant SDC2 methylation in stool-derived DNA was measured by linear target enrichment (LTE)-quantitative methylation-specific real-time PCR (qMSP). Duplicate reactions of meSDC2 LTE-qMSP test were performed for stool samples obtained from CRC patients representing all stages (0-IV) and asymptomatic individuals who were subsequently underwent colonoscopy examination. To determine the diagnostic value of test in CRC and control groups, sensitivity and specificity were evaluated by receiver operating characteristic curve analysis. Results: Of 585 subjects who could be evaluated, 245 had CRC, 44 had various sizes of adenomatous polyps, and 245 had negative colonoscopy results. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2% with AUC of 0.902 in detecting CRC (0-IV) not associated with tumor stage, location, sex, or age (P > 0.05), with a specificity of 90.2%. Sensitivity for detecting early stages (0-II) was 89.1% (114/128). This test also detected 66.7% (2/3) and 24.4% (10/41) of advanced and non-advanced adenomas, respectively. Conclusions: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for early detection of CRC patient with high specificity. Trial registration: ClinicalTrials.gov, NCT03146520, Registered 10 May 2017, Retrospectively registered; however, control arm was prospectively registered.

Original languageEnglish
Article number51
JournalClinical Epigenetics
Volume11
Issue number1
DOIs
Publication statusPublished - 2019 Mar 15

Fingerprint

Syndecan-2
Early Detection of Cancer
Colorectal Neoplasms
Methylation
DNA
Real-Time Polymerase Chain Reaction
Colonoscopy
Adenomatous Polyps
Routine Diagnostic Tests
ROC Curve
Adenoma
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Cite this

Han, Yoon Dae ; Oh, Tae Jeong ; Chung, Tae Ha ; Jang, Hui Won ; Kim, Youn Nam ; An, Sungwhan ; Kim, Nam Kyu. / Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. In: Clinical Epigenetics. 2019 ; Vol. 11, No. 1.
@article{4292274785c146488d78be204e9019a5,
title = "Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA",
abstract = "Background: Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. We have previously demonstrated that the presence of SDC2 methylation in stool DNA is significantly associated with the occurrence of CRC regardless of clinical stage. The aim of this study was to evaluate the clinical performance of stool DNA-based SDC2 methylation test for CRC. Methods: Aberrant SDC2 methylation in stool-derived DNA was measured by linear target enrichment (LTE)-quantitative methylation-specific real-time PCR (qMSP). Duplicate reactions of meSDC2 LTE-qMSP test were performed for stool samples obtained from CRC patients representing all stages (0-IV) and asymptomatic individuals who were subsequently underwent colonoscopy examination. To determine the diagnostic value of test in CRC and control groups, sensitivity and specificity were evaluated by receiver operating characteristic curve analysis. Results: Of 585 subjects who could be evaluated, 245 had CRC, 44 had various sizes of adenomatous polyps, and 245 had negative colonoscopy results. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2{\%} with AUC of 0.902 in detecting CRC (0-IV) not associated with tumor stage, location, sex, or age (P > 0.05), with a specificity of 90.2{\%}. Sensitivity for detecting early stages (0-II) was 89.1{\%} (114/128). This test also detected 66.7{\%} (2/3) and 24.4{\%} (10/41) of advanced and non-advanced adenomas, respectively. Conclusions: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for early detection of CRC patient with high specificity. Trial registration: ClinicalTrials.gov, NCT03146520, Registered 10 May 2017, Retrospectively registered; however, control arm was prospectively registered.",
author = "Han, {Yoon Dae} and Oh, {Tae Jeong} and Chung, {Tae Ha} and Jang, {Hui Won} and Kim, {Youn Nam} and Sungwhan An and Kim, {Nam Kyu}",
year = "2019",
month = "3",
day = "15",
doi = "10.1186/s13148-019-0642-0",
language = "English",
volume = "11",
journal = "Clinical Epigenetics",
issn = "1868-7075",
publisher = "Springer Verlag",
number = "1",

}

Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. / Han, Yoon Dae; Oh, Tae Jeong; Chung, Tae Ha; Jang, Hui Won; Kim, Youn Nam; An, Sungwhan; Kim, Nam Kyu.

In: Clinical Epigenetics, Vol. 11, No. 1, 51, 15.03.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA

AU - Han, Yoon Dae

AU - Oh, Tae Jeong

AU - Chung, Tae Ha

AU - Jang, Hui Won

AU - Kim, Youn Nam

AU - An, Sungwhan

AU - Kim, Nam Kyu

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Background: Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. We have previously demonstrated that the presence of SDC2 methylation in stool DNA is significantly associated with the occurrence of CRC regardless of clinical stage. The aim of this study was to evaluate the clinical performance of stool DNA-based SDC2 methylation test for CRC. Methods: Aberrant SDC2 methylation in stool-derived DNA was measured by linear target enrichment (LTE)-quantitative methylation-specific real-time PCR (qMSP). Duplicate reactions of meSDC2 LTE-qMSP test were performed for stool samples obtained from CRC patients representing all stages (0-IV) and asymptomatic individuals who were subsequently underwent colonoscopy examination. To determine the diagnostic value of test in CRC and control groups, sensitivity and specificity were evaluated by receiver operating characteristic curve analysis. Results: Of 585 subjects who could be evaluated, 245 had CRC, 44 had various sizes of adenomatous polyps, and 245 had negative colonoscopy results. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2% with AUC of 0.902 in detecting CRC (0-IV) not associated with tumor stage, location, sex, or age (P > 0.05), with a specificity of 90.2%. Sensitivity for detecting early stages (0-II) was 89.1% (114/128). This test also detected 66.7% (2/3) and 24.4% (10/41) of advanced and non-advanced adenomas, respectively. Conclusions: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for early detection of CRC patient with high specificity. Trial registration: ClinicalTrials.gov, NCT03146520, Registered 10 May 2017, Retrospectively registered; however, control arm was prospectively registered.

AB - Background: Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. We have previously demonstrated that the presence of SDC2 methylation in stool DNA is significantly associated with the occurrence of CRC regardless of clinical stage. The aim of this study was to evaluate the clinical performance of stool DNA-based SDC2 methylation test for CRC. Methods: Aberrant SDC2 methylation in stool-derived DNA was measured by linear target enrichment (LTE)-quantitative methylation-specific real-time PCR (qMSP). Duplicate reactions of meSDC2 LTE-qMSP test were performed for stool samples obtained from CRC patients representing all stages (0-IV) and asymptomatic individuals who were subsequently underwent colonoscopy examination. To determine the diagnostic value of test in CRC and control groups, sensitivity and specificity were evaluated by receiver operating characteristic curve analysis. Results: Of 585 subjects who could be evaluated, 245 had CRC, 44 had various sizes of adenomatous polyps, and 245 had negative colonoscopy results. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2% with AUC of 0.902 in detecting CRC (0-IV) not associated with tumor stage, location, sex, or age (P > 0.05), with a specificity of 90.2%. Sensitivity for detecting early stages (0-II) was 89.1% (114/128). This test also detected 66.7% (2/3) and 24.4% (10/41) of advanced and non-advanced adenomas, respectively. Conclusions: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for early detection of CRC patient with high specificity. Trial registration: ClinicalTrials.gov, NCT03146520, Registered 10 May 2017, Retrospectively registered; however, control arm was prospectively registered.

UR - http://www.scopus.com/inward/record.url?scp=85062963029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062963029&partnerID=8YFLogxK

U2 - 10.1186/s13148-019-0642-0

DO - 10.1186/s13148-019-0642-0

M3 - Article

C2 - 30876480

AN - SCOPUS:85062963029

VL - 11

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7075

IS - 1

M1 - 51

ER -